Last reviewed · How we verify
LiRIS®
At a glance
| Generic name | LiRIS® |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions (PHASE2)
- A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome (PHASE2)
- Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (PHASE2)
- A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions (PHASE1)
- Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LiRIS® CI brief — competitive landscape report
- LiRIS® updates RSS · CI watch RSS
- Allergan portfolio CI